This advertorial is sponsored by Medtronic.

“The registry is a perfect package as it brings together two elements greatly needed: a prospective randomised controlled trial [RCT] and real-world data,” says Phillipe Pereria (SLK-Kliniken, Heilbronn, Germany), principal investigator for the prospective observational Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Emprint Microwave Ablation Registry (CIEMAR). The registry, aiming to close the gap in real-life evidence, demonstrated high local tumour control with percutaneous microwave ablation for the treatment of colorectal liver metastases (CRLM).
“CIEMAR occupies a specific and essential niche in the evidence landscape for liver-directed therapies,” Pereira tells Interventional News. “Unlike the COLLISION trial—which was an RCT designed to prove non-inferiority under strict conditions—CIEMAR was conducted across 38 European centres in 13 countries, creating value in its ‘real-world’ validation of microwave ablation as a safe treatment with low procedure-related, or likely procedure-related, events reported.”
In his view, CIEMAR makes a “compelling contribution” to the current evidence base; with the addition of long-term follow-up, the registry provides data on the ability to achieve a complete technical response in a heterogeneous patient population and offers a robust assessment of complications in a non-trial or high-volume, academic setting.
Sharing their topline results, Pereira details that, in 500 patients and 976 lesions, local tumour control was achieved in close to 90% of patients at three-year follow-up. He adds that this result is despite 19% of tumours being located close to critical structures and that nearly all patients were treated with minimum ablative margins.
“Importantly, CIEMAR bridges between trial efficacy and clinical effectiveness,” Pereira says. “Trials like COLLISION prove that ablation works and set the ‘gold standard’ for how it should be done to achieve maximum oncological benefit. The CIEMAR registry shows that ablation does work in the real world, provided you maintain the standards established by the trials.”
Essentially, CIEMAR confirms that the results achieved in the COLLISION trial are not “lab grade”, attainable only by high-volume, experienced centres, says Pereira, but rather are translatable to the broader clinical community. He summarises that technical rigour—specifically regarding multidisciplinary discussion and the attainment of a safe ablation margin—are the greatest predictors of success, which, in his view, holds true regardless of whether you are in a trial or routine clinical practice.
Centre-level variations and “critical” safety margins
Pereira outlines that one of the “critical” realisations from CIEMAR is that local tumour progression is highly dependent on safety margins. He reflects that, when the “perfect conditions” of an RCT are removed, the importance of achieving adequate ablation margins becomes starkly evident. “The registry confirms that when the technical protocol (margin, power, time) is followed, outcomes remain high.”
For Martijn Meijerink (Amsterdam UMC, Amsterdam, Netherlands), COLLISION principal investigator and member of the CIEMAR steering committee, the registry confirms that microwave ablation should be considered the first-line treatment option in selected patients. However, adding nuance to this conclusion, Meijerink draws attention to variations in local tumour control in lower volume centres opting to use ultrasound alone and no confirmation software, stating that efforts must be made to ensure that favourable outcomes can be reproduced consistently across clinical practice.
“Across all centres, local tumour control should be over 90%, and CIEMAR shows you that we can even get close to 100%—three enrolled centres achieved this,” Meijerink points out. “We know from the COVER-ALL trial that confirmation software is important, so now that CIEMAR has shown that [microwave ablation] is first-line treatment for these patients, our next big step is to standardise our technique and make sure all centres are achieving no more than 10% local tumour recurrence.”
“Know your results,” he says, emphasising the importance of centres understanding their own recurrence rates. In his view, the heterogeneity observed in CIEMAR means that centres achieving lower local control should examine their technical approach and identify areas for improvement.
Yet, he cautions against interpreting the findings as evidence that the presence or absence of a particular technology alone determines outcomes. Some centres without confirmation software also achieved good results, while having the technology does not guarantee excellent local control. Instead, Meijerink argues that the findings support a broader effort to establish minimum standards for performing ablation.
“I think we should standardise the way we are doing these ablations,” he says, pointing to the need for computed tomography (CT) availability and sufficient operator experience.
For Pereira, the registry similarly reinforces the importance of maintaining technical standards established in clinical trials when translating ablation into routine practice. The combination of appropriate patient selection and multidisciplinary planning, as well as adequate margin assessment, he argues, will remain central to achieving consistent outcomes as the treatment is adopted more widely.
Patient selection and quality-of-life reports
While the registry supports the use of microwave ablation in appropriately selected patients, Pereira stresses that patient selection remains central to achieving durable local control. In particular, he points to smaller-volume disease, with a 3cm threshold remaining relevant for CRLM, while also highlighting tumour location and proximity to sensitive structures such as the bile ducts as factors that should be considered when determining treatment suitability.
“For future patient selection, we should favour patients with limited disease,” Pereira says. “We should prioritise smaller tumours—3cm for colorectal—and look at the experience, the technical plateau and the experience of the operator in the interventional oncology team.”
He adds that treatment planning should be multidisciplinary, with the strategy extending beyond the ablation procedure itself to consider subsequent management and any potential role for adjuvant treatment. Tumour biology may also become increasingly important in future patient selection, he suggests, given that individual metastases can demonstrate different molecular characteristics and responses to treatment.
Alongside local tumour control and safety, CIEMAR collected health-related quality-of-life data, including measures of function, global health and symptoms such as pain and fatigue. Pereira reports that the mid- and long-term quality-of-life profile was favourable, although he notes that patients may experience pain or fatigue around the time of ablation.
At three-year follow-up Pereira reports that global health was stable or improved by 68%, function score (including cognitive, emotion, physical, social) was stable or improved by 78%, and symptom scores (including fatigue, pain, shortness of breath, constipation, diarrhoea and insomnia) was stable or improved by 84%.
“The quality-of-life result is excellent,” he says, “and there are very few adverse effects,” notes Pereira, which not only benefits the patient, but also the healthcare system more broadly. “Following microwave ablation, the patient can leave the hospital a day later—can you imagine how long a patient stays in hospital following liver surgery?” Although reluctant to place ablation in direct competition with surgery, Pereira emphasises the cost benefit of reducing patient hospital stay.
Taking stock of key takeaways from the CIEMAR registry, Pereira states that future patient selection for percutaneous microwave ablation should be guided less by treatment convenience and more by the likelihood of achieving durable local control, with emphasis on tumour size, lesion location, ablative margins and multidisciplinary assessment.
“In practical terms, future patient selection should be margin- and anatomy-driven, with CIEMAR supporting the idea that ablation is not just a ‘less invasive option’, but a precision local therapy that works best when the tumour burden is limited, complete coverage is technically feasible, and the patient’s overall disease strategy is carefully planned,” Pereira concludes.











